Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Medivir AB ( (SE:MVIR) ) is now available.
Medivir AB announced its participation in the Redeye Life Science Day 2025, where CEO Jens Lindberg will present a new study involving the drug candidate fostrox in combination with lenvatinib for second-line liver cancer treatment. This study aims to demonstrate the superiority of the combination treatment over lenvatinib alone, potentially impacting Medivir’s position in the cancer treatment market by offering a significant improvement for patients with limited treatment options.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a pharmaceutical company that focuses on developing innovative cancer treatments, particularly in areas with high unmet medical needs. The company is dedicated to creating drug candidates for indications where current therapies are limited or non-existent, with a significant focus on fostroxacitabine bralpamide (fostrox) for liver cancer. Medivir operates through collaborations and partnerships, and its shares are listed on Nasdaq Stockholm’s Small Cap list.
Average Trading Volume: 789,779
Technical Sentiment Signal: Sell
Current Market Cap: SEK52.6M
See more insights into MVIR stock on TipRanks’ Stock Analysis page.